AHA today urged the Centers for Medicare & Medicaid Services to provide flexibility regarding the agency’s new COVID-19 test documentation requirement for the diagnostic-related group add-on payment.

“This new requirement will put substantial administrative burden on hospitals at a time when they are focusing their efforts and resources on critical patient care,” the association wrote. “Thus, we urge CMS to allow provider documentation to suffice if the test result is unavailable.”

The Coronavirus Aid, Relief, and Economic Security Act provided a 20% add-on to the inpatient prospective payment system DRG rate for patients diagnosed with COVID-19 during the public health emergency. CMS recently added a requirement to have a positive COVID-19 laboratory test documented in the patient’s medical record in order for the claim to be eligible. The new requirement would be applied to admissions on or after Sept. 1, 2020.

“We have heard from our hospital members that acquiring test results from other health care providers, local testing centers and other third party entities can be a burdensome process, sometimes resulting in long delays or unobtainable results,” the letter notes. “In order to receive the add-on payment, hospitals would have to dedicate considerable time and effort to obtain a patient’s third party result to manually add into the medical record, and in some cases would ultimately have to re-test the patient.”

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA Dec. 11 expressed support for the reintroduction of the Future Advancement of Academic Nursing, bicameral legislation that would increase nursing…
Headline
The Centers for Medicare & Medicaid Services released guidance Dec. 8 for states implementing Medicaid community engagement requirements outlined by the…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…